Omeros Corporation

Company Overview

Business Model: Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company targets large-market and orphan indications, primarily in immunologic diseases (including complement-mediated diseases and cancers related to immune system dysfunction) and addictive and compulsive disorders. Revenue generation is currently primarily through royalty and milestone payments from the sale of its former commercial ophthalmology product, OMIDRIA, and grant funding, as it is a clinical-stage company without commercialized products from its current pipeline.

Market Position: Omeros Corporation operates in the highly competitive pharmaceutical and biotechnology industry, characterized by established large pharmaceutical and biotechnology companies, as well as smaller entities. The company's complement-targeted therapeutic development programs are primarily focused on diseases associated with the lectin and/or alternative pathways of complement, where it is developing inhibitors of MASP-2 and MASP-3. Omeros Corporation believes its MASP-3 inhibitor, zaltenibart, has attributes that favorably differentiate it from other marketed and in-development alternative pathway inhibitors. The company owns or holds worldwide exclusive licenses to rights related to MASP-2, MASP-3, and their therapeutic applications.

Recent Strategic Developments:

• Narsoplimab BLA Resubmission: In March 2025, Omeros Corporation resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission includes new statistical analyses comparing survival data from its pivotal trial to an external historical control group and data from an expanded access program.
• OMIDRIA Royalty Monetization: In February 2024, Omeros Corporation sold an expanded interest in its future OMIDRIA royalties to DRI Healthcare Acquisitions LP for $115.5 million. This agreement grants DRI Healthcare Acquisitions LP all royalties on U.S. net sales of OMIDRIA payable between January 1, 2024, and December 31, 2031. Omeros Corporation retains rights to non-U.S. royalties and U.S. royalties after December 31, 2031, and is eligible for two milestone payments of up to $27.5 million each in January 2026 and January 2028 based on U.S. net sales thresholds.
• Secured Credit Facility: In June 2024, Omeros Corporation entered into a Credit and Guaranty Agreement for a senior secured term loan facility of up to $92.1 million, with an initial term loan of $67.1 million fully funded. This facility is secured by substantially all of Omeros Corporation's assets, excluding OMIDRIA royalty interests.
• 2026 Notes Repurchase: Concurrently with the credit facility, Omeros Corporation used the initial term loan and cash on hand to repurchase $118.1 million aggregate principal amount of its 5.25% convertible senior notes due 2026, reducing the outstanding principal balance by 55%.
• Zaltenibart Phase 3 Initiation: Omeros Corporation has initiated its Phase 3 clinical development program for zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) and plans to initiate a Phase 3 trial in complement 3 glomerulopathy (C3G) following completion of its ongoing Phase 2 study.
• NIDA Grant for OMS527: In April 2023, Omeros Corporation was awarded a $6.24 million grant from the National Institute on Drug Abuse (NIDA) to develop its lead orally administered PDE7 inhibitor compound, OMS527, for the treatment of cocaine use disorder. Preclinical studies for cocaine interaction/toxicology have been successfully completed, and a NIDA-funded Phase 1b clinical trial in adult CUD patients is initiating.

Geographic Footprint: Omeros Corporation's principal executive offices and laboratories are located in Seattle, Washington, U.S. The company conducts clinical trials in multiple countries, with 120 clinical investigative sites across 30 countries chosen for the zaltenibart Phase 3 program in PNH. While OMIDRIA was marketed in the U.S. until 2021, Omeros Corporation retains the right to receive royalties on net sales of OMIDRIA outside the U.S. and is evaluating potential arrangements for narsoplimab commercialization in Europe if approved by the European Medicines Agency (EMA).

Financial Performance

Revenue Analysis

Omeros Corporation is a clinical-stage biopharmaceutical company and does not report revenue from commercialized products in its current pipeline. Its primary source of income from continuing operations is "Interest and other income," which includes interest earned on investments and NIDA grant income. Revenue from the former commercial product OMIDRIA is classified under discontinued operations.

Profitability Metrics:

• Gross Margin: Not applicable (Gross Profit not reported for continuing operations).
• Operating Margin: Not applicable (Operating Income is a loss, and no revenue from continuing operations is reported as a single line item for calculation).
• Net Margin: Not applicable (Net Income is a loss, and no revenue from continuing operations is reported as a single line item for calculation).

Investment in Growth:

• R&D Expenditure: $119.52 million (70.62% of Total Costs and Expenses)
• Capital Expenditures: $0.17 million
• Strategic Investments:
  • Narsoplimab (MASP-2 program): $35.91 million in clinical R&D.
  • Zaltenibart (MASP-3 program): $24.99 million in clinical R&D.
  • OMS1029 (MASP-2 program): $4.06 million in clinical R&D.
  • Preclinical research and development: $6.47 million, including increased oncology research and cocaine addiction work (partially NIDA-funded).

Business Segment Analysis

Omeros Corporation operates in one business segment, focusing on the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases and addictive/compulsive disorders. Therefore, segment-specific financial performance, product portfolio, and market dynamics are integrated into the overall company analysis.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Omeros Corporation repurchased and retired 3.20 million shares of common stock for an aggregate purchase price of $11.85 million in 2024. In 2023, 1.80 million shares were repurchased for $4.65 million. The share repurchase program was terminated in June 2024 upon execution of the Credit Agreement, which prohibits common stock repurchases unless agreed to by the lenders.
• Dividend Payments: Omeros Corporation has never declared or paid any cash dividends on its capital stock and is precluded from paying cash dividends under the terms of its secured credit facility. The company does not anticipate paying any cash dividends in the foreseeable future, planning to invest all available funds and future earnings in business development and growth.
• Dividend Yield: 0.0%
• Future Capital Return Commitments: No future capital return commitments are authorized or planned due to current financial strategy and debt covenants.

Balance Sheet Position (as of December 31, 2024):

• Cash and Equivalents: $3.40 million
• Total Debt: $187.58 million (comprising $97.18 million in convertible senior notes, net, and $90.41 million in term debt, net).
• Net Cash Position: $(184.18) million (Cash and cash equivalents + Short-term investments - Total Debt).
• Credit Rating: Not disclosed.
• Debt Maturity Profile:
  • 2026 Notes: $97.86 million principal amount due February 15, 2026.
  • Term Loan: $67.08 million principal amount due June 3, 2028.
  • Mandatory Prepayment: A $20.0 million mandatory prepayment on the Term Loan is expected in November 2025, along with a $1.0 million prepayment penalty, if certain conditions related to the 2026 Notes are met.

Cash Flow Generation (for the year ended December 31, 2024):

• Operating Cash Flow: $(148.80) million
• Free Cash Flow: $(148.97) million (Operating Cash Flow of $(148.80) million minus Capital Expenditures of $0.17 million).
• Cash Conversion Metrics: Not explicitly disclosed in the filing.

Operational Excellence

Production & Service Model: Omeros Corporation is a clinical-stage biopharmaceutical company that does not own or operate internal manufacturing facilities capable of producing sufficient quantities of its product candidates under current Good Manufacturing Practices (cGMP) for clinical studies or commercial use. The company relies on contract manufacturers for the production, storage, and distribution of its product candidates. This includes Lonza Biologics Tuas Pte. Ltd. for commercial production of narsoplimab drug substance and Vetter Pharma International, GmbH for aseptic filling of narsoplimab in vials. A third-party vendor is used for labeling and final packaging.

Supply Chain Architecture: Omeros Corporation's supply chain is structured around third-party contract manufacturing and relies on external suppliers for active pharmaceutical ingredients (APIs), excipients, raw materials, and packaging. Key Suppliers & Partners:

• Drug Substance Manufacturing: Lonza Biologics Tuas Pte. Ltd. - manufactures narsoplimab drug substance for commercial production and provides regulatory support. Omeros Corporation is obligated to purchase a minimum number of batches annually after the first commercial sale.
• Drug Product Filling: Vetter Pharma International, GmbH - aseptically fills narsoplimab in vials for clinical or commercial use.
• Packaging & Labeling: Third-party vendor - for final packaging and labeling of narsoplimab finished goods.
• API/Excipient Suppliers: Third-party suppliers - provide necessary ingredients and materials for product candidate manufacturing.

Facility Network:

• Principal Office & Laboratory: Approximately 111,926 square feet in Seattle, Washington, U.S., including 6,111 square feet subleased to third parties. The lease term extends through November 2027, with two five-year extension options.
• Manufacturing: Relies entirely on third-party contract manufacturing facilities.
• Research & Development: Internal laboratories for analytical method development, bioanalytical testing, formulation, stability testing, and small-scale compounding.

Operational Metrics: No specific operational metrics such as capacity utilization or efficiency measures were disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Omeros Corporation has retained all worldwide marketing and distribution rights for its product candidates. If narsoplimab is approved for marketing in the U.S. for TA-TMA, the company expects to utilize an internal sales force, with hiring of specialty sales representatives planned upon reaching certain FDA review milestones. For potential approval of narsoplimab in Europe, Omeros Corporation intends to pursue partnerships and/or commercial services arrangements with third parties.

Distribution Channels:

• Direct Sales: Planned internal sales force for U.S. commercialization of narsoplimab, if approved.
• Channel Partners: Intends to enter into partnerships and/or commercial services arrangements with third parties for marketing and sales in Europe, if narsoplimab is approved by the EMA.
• Wholesalers: Expects to utilize one or more wholesalers for distribution of narsoplimab, if approved in the U.S.

Customer Portfolio:

• Enterprise Customers: Not explicitly detailed, as the company is clinical-stage.
• Strategic Partnerships: Rayner Surgical Inc. (for OMIDRIA royalties), DRI Healthcare Acquisitions LP (for OMIDRIA royalty monetization), Athyrium Capital Management, LP and Highbridge Capital Management, LLC (lenders), Xencor, Inc. (technology license for zaltenibart), Daiichi Sankyo Co., Ltd. (license for PDE7 inhibitors), National Institute on Drug Abuse (NIDA) (grant funding for OMS527).
• Customer Concentration: Not applicable for current pipeline products as they are not yet commercialized.

Geographic Revenue Distribution:

• U.S.: Primary focus for narsoplimab commercialization efforts.
• Europe: Targeted for narsoplimab commercialization through partnerships if EMA approval is granted.
• International: Omeros Corporation retains rights to royalties on net sales of OMIDRIA outside the U.S., but these have not been significant to date. Clinical trials for zaltenibart are conducted across 30 countries.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical and biotechnology industry is highly competitive, characterized by rapid technological change and the presence of numerous established large pharmaceutical and biotechnology companies, as well as smaller companies. Competition involves developing and marketing products that are less expensive, more effective, or safer, commercializing products faster, and possessing greater resources for R&D, manufacturing, and market penetration.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: Omeros Corporation's product candidates will face competition from a number of complement-targeted therapeutics that are in advanced stages of clinical development or have been approved for commercial use. These include:

• Soliris® (eculizumab)
• Ultomiris® (ravulizumab-cwvz)
• Empaveli® (pegcetacoplan)
• Tavneos® (avocopan)
• PiaSky® (crovalimab-akkz)
• Voydeya (danicopan)
• Fabhalta® (iptacopan)

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in the complement system inhibition space, as well as in oncology and addiction/movement disorders, pose potential threats.

Competitive Response Strategy: Omeros Corporation's strategy involves advancing its proprietary MASP-2 and MASP-3 inhibitors, with zaltenibart's Phase 3 PNH studies designed for head-to-head comparisons with C5 inhibitors to potentially demonstrate superiority. The company also focuses on orphan drug designations and expedited development pathways (e.g., breakthrough therapy designation for narsoplimab in TA-TMA) to gain market access and competitive advantage. Its oncology program is operating in "stealth mode" to confirm results and generate new intellectual property.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Regulatory Approval Uncertainty: Failure to obtain or maintain regulatory approval for product candidates (e.g., narsoplimab's prior Complete Response Letter from FDA) would prevent commercialization. The resubmitted BLA for narsoplimab in TA-TMA may not be approved, or approval may be delayed, due to various factors including interpretation of data, comparability of control groups, or manufacturing support issues.
• Coverage and Reimbursement: Inadequate or delayed coverage and reimbursement from government and private payers for any future commercialized products would severely impact revenue and profitability.
• OMIDRIA Royalty Dependence: Future capital requirements are partially dependent on milestone and royalty payments from Rayner Surgical Inc. and DRI Healthcare Acquisitions LP, which are subject to OMIDRIA sales performance and regulatory changes (e.g., separate payment status under Medicare Part B).
• Unpredictable Operating Results: Quarterly and annual results are difficult to predict due to factors like OMIDRIA sales, collaboration payments, R&D investment timing, and the timing/magnitude of product approvals and commercial launch expenses.
• Government Policy Changes: Significant changes in U.S. federal government size, structure, powers, and policy actions (e.g., tariffs, federal grant freezes, Inflation Reduction Act impacts on Medicare drug reimbursement) could cause economic disruptions and adversely affect business operations, supply chain, and funding.
• Competition: Competitors may develop superior, cheaper, or faster-to-market products, or possess greater resources, potentially diminishing the success of Omeros Corporation's products.
• Resource Allocation: Limited resources may be expended on less promising product candidates or indications, leading to missed opportunities.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Manufacturing Reliance: Omeros Corporation has no internal commercial or clinical manufacturing capacity and relies solely on third-party contract manufacturers. Difficulties in securing sufficient capacity, maintaining commercially reasonable terms, or ensuring compliance with cGMP could delay clinical trials, regulatory submissions, or commercial supply.
• Supplier Dependency: Inability to obtain APIs, excipients, test kits, and other materials from third-party suppliers on commercially reasonable terms or in required quantities could delay development and commercialization.
• Capacity Constraints: Contract manufacturers may face difficulties with formulation, manufacturing, supply chain, or release processes, leading to delays, recalls, or inadequate supply.
• Geographic Concentration: Clinical trials in regions affected by armed conflict or political instability (e.g., Ukraine for zaltenibart) could disrupt enrollment, retention, drug supply, or data integrity.

Operational Metrics: Not explicitly disclosed.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern Doubt: Management has concluded that substantial doubt exists regarding Omeros Corporation's ability to continue as a going concern due to recurring losses, negative cash flows, limited cash resources (constrained by a $25.0 million minimum cash covenant), and upcoming debt maturities.
• Capital Raising Inability: Inability to raise additional capital through equity offerings, debt financings, collaborations, or asset sales when needed would force delays, scale-backs, or discontinuation of development programs.
• Indebtedness Restrictions: The Credit Agreement imposes restrictive covenants (e.g., on incurring debt, granting liens, asset disposal, dividends, stock repurchases, exclusive IP licensing) that limit operating and financial flexibility. Default could lead to acceleration of repayment obligations and loss of pledged assets, including intellectual property.
• Debt Servicing: Significant indebtedness (2026 Notes, Term Loan) requires substantial cash flow for service and repayment, reducing funds for operations and growth, and increasing vulnerability to adverse economic conditions.
• Foreign Exchange: Not explicitly detailed as a material risk, but international operations and potential European commercialization imply exposure.
• Credit & Liquidity: Limited cash resources and potential inability to access capital markets or strategic alliances on favorable terms pose significant liquidity risks.

Regulatory & Compliance Risks:

• Extensive Government Regulation: Subject to extensive U.S. and international regulations (FDA, EMA, etc.) covering all stages of product lifecycle. Failure to comply can result in severe sanctions, delays, or withdrawal of approvals.
• Post-Approval Requirements: Even after approval, ongoing compliance with cGMP, pharmacovigilance, advertising restrictions, and potential post-marketing studies or REMS can be costly and burdensome.
• Healthcare Compliance Laws: Commercialization is subject to federal and state healthcare compliance laws (Anti-Kickback Statute, False Claims Act, Sunshine Act, Foreign Corrupt Practices Act), requiring significant resources for compliance and posing risks of penalties for violations.
• Intellectual Property Protection: Difficulty and cost in obtaining, maintaining, and defending patent and trade secret protection for product candidates and technologies. Patent infringement litigation is complex, costly, and unpredictable, with potential for adverse outcomes (injunctions, damages).
• Changes in Regulatory Landscape: Unpredictable changes in regulatory policies, legislation (e.g., healthcare reform), or interpretations could prevent, limit, or delay approvals.

Geopolitical & External Risks

Geopolitical Exposure:

• Geographic Dependencies: Clinical trials in politically unstable or conflict-affected regions (e.g., Ukraine) can lead to disruptions in patient enrollment, follow-up, drug supply, and data integrity.
• Trade Relations: New tariffs or trade policies (e.g., U.S. administration actions) could increase production costs, disrupt supply chains, and reduce competitiveness.
• Natural Disasters/Other Events: Unplanned events (natural disasters, power outages, cyber-attacks) could disrupt operations, damage critical infrastructure, and lead to business continuity issues, potentially exceeding insurance coverage.

Innovation & Technology Leadership

Research & Development Focus: Omeros Corporation's R&D organization integrates expertise in discovery research, preclinical development, product formulation, analytical and medicinal chemistry, manufacturing, clinical development, and regulatory/quality assurance. The company makes disciplined strategic decisions for its R&D programs, leveraging market information and key opinion leaders. Core Technology Areas:

• Complement System Inhibition:
  • MASP-2 (Lectin Pathway): Lead product candidate narsoplimab (human monoclonal antibody) for TA-TMA, severe COVID-19, ARDS, and PASC. Also developing OMS1029 (long-acting antibody) for chronic indications and small-molecule MASP-2 inhibitors for oral administration.
  • MASP-3 (Alternative Pathway): Lead product candidate zaltenibart (human monoclonal antibody) for PNH and C3G. Also developing small-molecule MASP-3 inhibitors for oral administration.
• Phosphodiesterase 7 (PDE7) Inhibition: OMS527 program for addiction and movement disorders (e.g., cocaine use disorder, levodopa-induced dyskinesia). Based on discoveries linking PDE7 to these conditions.
• Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Program: OMS405 program for addiction to substances of abuse (opioids, nicotine, alcohol), based on discoveries linking PPARγ to addiction disorders.
• Oncology Platform: Developing a portfolio of next-generation biologics, including novel targeted drug conjugates, and an adoptive T-cell technology combined with an immunostimulator for a wide range of cancers. This program is currently in "stealth mode."

Innovation Pipeline:

• Narsoplimab: BLA resubmitted for TA-TMA (FDA review expected September 2025); MAA submission targeted for EMA in H1 2025. Continued development for ARDS and PASC, including a diagnostic assay for lectin pathway hyperactivation.
• OMS1029: Phase 1 studies completed, supporting once-quarterly subcutaneous administration. Evaluating potential chronic indications for Phase 2 development.
• Zaltenibart: Phase 3 programs initiated for PNH (head-to-head comparisons with C5 inhibitors planned). Phase 2 program ongoing for C3G, with plans to initiate Phase 3 after completion. Received rare pediatric disease designation for C3G.
• OMS527: NIDA-funded Phase 1b study in adult CUD patients initiating, with preliminary data readout targeted by year-end 2025.
• Preclinical Programs: Small-molecule MASP-2 and MASP-3 inhibitors advancing; oncology platform in preclinical proof-of-concept studies.

Intellectual Property Portfolio (as of March 31, 2025):

• Patent Strategy: Omeros Corporation owns or holds worldwide exclusive licenses to 81 issued patents and 64 pending patent applications in the U.S., and 1,443 issued patents and 655 pending patent applications in foreign markets.
  • MASP-2 Program: 42 issued U.S. patents, 33 pending U.S. applications; 861 issued foreign patents, 474 pending foreign applications. Terms expire as late as 2038 (issued) and 2043 (pending).
  • MASP-3 Program: 5 issued U.S. patents, 8 pending U.S. applications; 212 issued foreign patents, 109 pending foreign applications. Terms expire as late as 2037 (issued) and 2043 (pending).
  • PPARγ Program: 3 issued U.S. patents, 1 pending U.S. application; 42 issued foreign patents, 1 pending foreign application. Terms expire as late as 2030.
  • PDE7 Program: 5 issued U.S. patents, 4 pending U.S. applications; 115 issued foreign patents, 13 pending foreign applications. Terms expire as late as 2031 (issued) and 2043 (pending). Includes licensed rights from Daiichi Sankyo Co., Ltd.
  • Oncology Program: 2 pending U.S. patent applications.
• Trademark Strategy: Registered "OMEROS" and its alpha/omega logo in the USPTO and various foreign jurisdictions. Registered and pending trademark applications for "YARTEMLEA" (expected brand name for narsoplimab).
• Trade Secrets: Relies on trade secrets where patent protection is not appropriate or obtainable, protected by employee agreements.

Technology Partnerships:

• Xencor, Inc.: Exclusive license to Xencor, Inc.'s Xtend Fc technology for zaltenibart, with options for additional antibodies. Milestone payments up to $65.0 million per antibody ($5.0 million paid in August 2023, $10.0 million expected in 2025). Mid-single digit royalties on net sales.
• Daiichi Sankyo Co., Ltd.: Exclusive worldwide license to PDE7 inhibitors for movement, addiction, compulsive disorders, and other specified indications. Milestone payments up to $33.5 million (or $23.5 million for one indication). Low single-digit percentage royalties on net sales.
• National Institute on Drug Abuse (NIDA): Grant funding for OMS527 development in cocaine use disorder.
• Emory University: Collaboration for evaluating OMS527 as a potential treatment for levodopa-induced dyskinesia.
• The New York State Psychiatric Institute: Collaborated on Phase 2 clinical trials for PPARγ agonists in addiction, with NIDA funding and oversight.

Leadership & Governance

Executive Leadership Team (as of March 13, 2025)

Leadership Continuity: The company's success depends significantly on its management team. Omeros Corporation does not maintain key-person life insurance policies other than on the life of Gregory A. Demopulos, M.D.

Board Composition: The Board of Directors is classified. Specific details on independence, expertise areas, and committee structure are incorporated by reference to the 2025 Annual Meeting of Shareholders proxy statement.

Human Capital Strategy

Workforce Composition (as of December 31, 2024):

• Total Employees: 202 full-time employees.
• Geographic Distribution: Not explicitly detailed beyond the principal office in Seattle, Washington, U.S.
• Skill Mix: 136 employees in research and development (including 6 M.Ds and 40 Ph.Ds), 19 in sales and marketing, and 47 in finance, legal, business development, and administration (including 1 M.D. and 1 Ph.D.).

Talent Management: Acquisition & Retention:

• Hiring Strategy: Omeros Corporation maintains a rigorous, highly selective, and time-consuming hiring process.
• Retention Metrics: Not explicitly disclosed.
• Employee Value Proposition: Compensation philosophy, benefits, and culture are not explicitly detailed in the filing.

Diversity & Development:

• Diversity Metrics: Not explicitly disclosed.
• Development Programs: Not explicitly detailed.
• Culture & Engagement: Employee relations are considered good.

Environmental & Social Impact

No material information regarding Environmental & Social Impact initiatives or commitments was explicitly disclosed in the provided 10-K filing.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed in the filing.
• Economic Sensitivity: Not explicitly detailed in the filing.
• Industry Cycles: Not explicitly detailed in the filing.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Omeros Corporation's product candidates are subject to extensive regulation by government authorities in the U.S. (FDA under FDCA and PHSA), the EU (EMA and national regulators), and other countries. The regulatory process involves formulation and manufacturing development, preclinical testing, IND/CTA submissions, human clinical trials (Phase 1, 2, 3), stability assessment, and NDA/BLA/MAA submissions. Compliance with cGMP, GCP, and other regulations is required throughout development and post-approval. Industry-Specific Regulations:

• FDA Approval Process: Requires demonstration of safety and efficacy, favorable benefit-risk profile, manufacturing quality, and adequate labeling. Subject to agency discretion, potential delays, and requirements for additional studies or information.
• Expedited Programs: Narsoplimab has received breakthrough therapy designation (U.S.) and orphan drug designation (U.S. and EU) for TA-TMA, and zaltenibart has orphan drug designation for PNH and rare pediatric disease designation for C3G, which may offer expedited development and review opportunities.
• Post-Marketing Requirements: Includes pharmacovigilance, adverse event reporting, quality control, advertising/promotion restrictions, and potential post-marketing studies or Risk Evaluation and Mitigation Strategies (REMS).
• Foreign Regulatory Requirements: Separate approvals and compliance with varying requirements are needed for non-U.S. markets, with processes similar to FDA but potentially different timelines and standards.

Trade & Export Controls:

• Drug Supply Chain Security Act (DSCSA): Manufacturers are subject to product tracking, tracing, serialization, verification, and record-keeping requirements in the U.S. Similar anti-counterfeiting and serialization requirements exist in the EU.
• Export Restrictions/Sanctions: Not explicitly detailed as a specific risk, but general compliance with international trade laws is implied.

Legal Proceedings: As of the filing date, Omeros Corporation was not involved in any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 1.3% (2024), 0.0% (2023), -0.0% (2022) for continuing operations.
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: The Tax Cuts and Jobs Act (2017) requires capitalization and amortization of research and experimental expenditures starting in 2022, impacting tax expense.
• NOL Carryforwards (as of December 31, 2024): Approximately $80.41 million federal NOLs (pre-2018 expire 2035-2037, post-2018 do not expire) and $104.77 million state NOLs.
• Research and Development Tax Credits (as of December 31, 2024): $104.77 million, expiring between 2025 and 2044.
• Valuation Allowance: A full valuation allowance of $283.96 million is established against net deferred tax assets as of December 31, 2024, as it is more likely than not that these assets will not be realized.
• Unrecognized Tax Benefits: Total gross unrecognized tax benefits of $4.46 million as of December 31, 2024, including $0.20 million in interest and penalties.

Insurance & Risk Transfer

Risk Management Framework: Omeros Corporation utilizes a range of internal and external resources to assess and identify cybersecurity threats and vulnerabilities, including publications, reports, external auditors, consulting firms, and managed security service providers. It implements technical, physical, and organizational measures (e.g., data encryption, network security controls, access controls, continuous monitoring) and maintains business continuity and disaster recovery plans. A risk-weighted approach is taken for third-party service provider cybersecurity risks, involving due diligence and contractual safeguards.

Insurance Coverage: Omeros Corporation may be exposed to product liability claims inherent in the biopharmaceutical industry. Product liability insurance is generally expensive and may not provide sufficient coverage. The company does not explicitly detail its specific insurance coverage limits or self-insurance retention levels in the filing. It may not carry sufficient business interruption insurance to compensate for all losses from natural disasters or other events.